Drug Profile
Disufenton - Oblato
Alternative Names: Disufenton sodium - Oblato; Oklahoma Nitrone 007; OKN-007Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Oklahoma Medical Research Foundation
- Developer Oblato; Oklahoma Medical Research Foundation
- Class Anti-ischaemics; Antineoplastics; Benzenesulfonates; Neuroprotectants; Nitrogen oxides; Small molecules
- Mechanism of Action Oxygen radical scavengers; Sulfatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma
- Preclinical Colorectal cancer; Diffuse intrinsic pontine glioma; Endometrial cancer; Uterine cancer
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Glioblastoma(In volunteers) in USA (PO, Tablet)
- 25 Oct 2022 Phase-I clinical trials in Glioblastoma (Second-line therapy or greater, Recurrent) in USA (PO) (NCT05561374)
- 24 Oct 2022 Oblato completes enrollment in a phase II trial for Glioblastoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)